September 29, 2021 -- Thermo Fisher Scientific is accepting new proposals that leverage next-generation sequencing (NGS) for its Oncomine Clinical Research Grant.
The firm aims to fund clinical research programs that leverage NGS in solid tumors and hematology-oncology applications. Recipients receive up to $200,000 in reagents and general funding.
Grant proposals can be submitted until October 25, 2021.